Wu X and colleagues analyzed the mechanism and targets of curcumin in treating AD using network pharmacology, and the results suggest that curcumin inhibits NF-κB transcription and protein levels, thereby suppressing TNF-α, IL-1β, cyclooxygenase-2 (COX-2), and inducible nitric oxide synthase (iNOS), reducing inflammation and cell apoptosis and ultimately decreasing Aβ deposition [131]. The gene discussed is PTGS2; the disease is Alzheimer disease.